The opioid crisis has been declared a national health emergency. Access our insights, formed by real-world evidence, on the affected population, prescribing trends, and emerging policy initiatives. Rely on our fact-based coverage.
New analysis from Avalere finds that the quantity of retail fentanyl sold across the US dropped by an average of 28%, between 2014 and 2017.
The Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, signed into law on October 24, 2018, takes aim at the opioid crisis from multiple angles.
New Avalere research finds that health plan members enrolled in plans that cover abuse-deterrent formulations (ADFs) of opioids have a lower risk of opioid abuse (OA) and overdose (OD) and lower opioid abuse-related hospitalizations than people in plans that do not offer coverage of ADF opioids.
Shift in clinical practice as far back as 30 years ago planted the seeds for the current opioid epidemic. New research by Avalere Health finds that between the mid-1980s and 1990s, individual pharmaceutical manufacturers, national scientific bodies, and professional societies began a push to treat pain more aggressively.
Maine had the greatest decline at 25% compared with the national average of 11%.
The House and Senate are advancing legislative packages aimed at mitigating the crisis.
Coordinated information sharing can facilitate the delivery of integrated care to patients using both physical and behavioral health services.
In response to the concern that overprescribing is a driver of the opioid crisis, payers are limiting opioid fills as one solution.
New research from Avalere Health finds 11 states and DC lack an adequate number of providers certified to prescribe buprenorphine, a medicine used to prevent relapse in people with opioid dependence.
Resource presents trends in opioid painkiller prescriptions and deaths due to misuse and abuse.
New research from Avalere finds that despite the innovation of abuse-deterrent properties and labeling for branded opioids, Medicare Part D plan coverage for these products is declining rapidly.